Delara Motlagh, PhD, MS, EMBA, Terumo Blood and Cell Technologies, Lakewood, CO, discusses hurdles associated with automating processes within the cell and gene therapy (CGT) field. Despite collaborative efforts between manufacturers and regulatory authorities, supply chain issues persist. Dr Motlagh additionally highlights the need for companies to fully understand every aspect of their current and future products. This interview took place at Advanced Therapies Week 2022.
Delara Motlagh, PhD, MS, EMBA, is an employee of Terumo Blood and Cell Technologies.